Keywords: Ablynx, Boehringer Ingelheim, Nanobodies, Research
Ablynx gets 3 million-euro milestone from Boehringer Ingelheim
Article | 02 October 2009
Belgium’s Ablynx says that it will receive milestone payments totalling 3 million euros ($4.4 million) from independent German drug major Boehringer ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
